Risk assessment and predicting outcomes in patients with depressive symptoms: a review of potential role of peripheral blood based biomarkers

Bhautesh D. Jani, Gary McLean, Barbara I. Nicholl, Sarah J.E. Barry, Naveed Sattar, Frances S. Mair, Jonathan Cavanagh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Depression is one of the major global health challenges and a leading contributor of health related disability and costs. Depression is a heterogeneous disorder and current methods for assessing its severity in clinical practice rely on symptom count, however this approach is unreliable and inconsistent. The clinical evaluation of depressive symptoms is particularly challenging in primary care, where the majority of patients with depression are managed, due to the presence of co-morbidities. Current methods for risk assessment of depression do not accurately predict treatment response or clinical outcomes. Several biological pathways have been implicated in the pathophysiology of depression; however, accurate and predictive biomarkers remain elusive. We conducted a systematic review of the published evidence supporting the use of peripheral biomarkers to predict outcomes in depression, using Medline and Embase. Peripheral biomarkers in depression were found to be statistically significant predictors of mental health outcomes such as treatment response, poor outcome and symptom remission; and physical health outcomes such as increased incidence of cardiovascular events and deaths, and all-cause mortality. However, the available evidence has multiple methodological limitations which must be overcome to make any real clinical progress. Despite extensive research on the relationship of depression with peripheral biomarkers, its translational application in practice remains uncertain. In future, peripheral biomarkers identified with novel techniques and combining multiple biomarkers may have a potential role in depression risk assessment but further research is needed in this area.
LanguageEnglish
Article number18
Number of pages14
JournalFrontiers in Human Neuroscience
Volume9
DOIs
Publication statusPublished - 2 Feb 2015

Fingerprint

Biomarkers
Risk Assessment
Risk assessment
Blood
Depression
Health
Primary Care
Pathophysiology
Review
Predict
Morbidity
Disability
Mortality
Inconsistent
Research
Disorder
Predictors
Pathway
Incidence
Count

Keywords

  • peripheral biomarkers
  • depression
  • treatment response
  • risk assessment
  • major depressive disorder
  • MDD

Cite this

Jani, Bhautesh D. ; McLean, Gary ; Nicholl, Barbara I. ; Barry, Sarah J.E. ; Sattar, Naveed ; Mair, Frances S. ; Cavanagh, Jonathan. / Risk assessment and predicting outcomes in patients with depressive symptoms : a review of potential role of peripheral blood based biomarkers. In: Frontiers in Human Neuroscience. 2015 ; Vol. 9.
@article{1fc8f05aa80849a68a124e841cb73704,
title = "Risk assessment and predicting outcomes in patients with depressive symptoms: a review of potential role of peripheral blood based biomarkers",
abstract = "Depression is one of the major global health challenges and a leading contributor of health related disability and costs. Depression is a heterogeneous disorder and current methods for assessing its severity in clinical practice rely on symptom count, however this approach is unreliable and inconsistent. The clinical evaluation of depressive symptoms is particularly challenging in primary care, where the majority of patients with depression are managed, due to the presence of co-morbidities. Current methods for risk assessment of depression do not accurately predict treatment response or clinical outcomes. Several biological pathways have been implicated in the pathophysiology of depression; however, accurate and predictive biomarkers remain elusive. We conducted a systematic review of the published evidence supporting the use of peripheral biomarkers to predict outcomes in depression, using Medline and Embase. Peripheral biomarkers in depression were found to be statistically significant predictors of mental health outcomes such as treatment response, poor outcome and symptom remission; and physical health outcomes such as increased incidence of cardiovascular events and deaths, and all-cause mortality. However, the available evidence has multiple methodological limitations which must be overcome to make any real clinical progress. Despite extensive research on the relationship of depression with peripheral biomarkers, its translational application in practice remains uncertain. In future, peripheral biomarkers identified with novel techniques and combining multiple biomarkers may have a potential role in depression risk assessment but further research is needed in this area.",
keywords = "peripheral biomarkers, depression, treatment response, risk assessment, major depressive disorder, MDD",
author = "Jani, {Bhautesh D.} and Gary McLean and Nicholl, {Barbara I.} and Barry, {Sarah J.E.} and Naveed Sattar and Mair, {Frances S.} and Jonathan Cavanagh",
year = "2015",
month = "2",
day = "2",
doi = "10.3389/fnhum.2015.00018",
language = "English",
volume = "9",
journal = "Frontiers in Human Neuroscience",
issn = "1662-5161",

}

Risk assessment and predicting outcomes in patients with depressive symptoms : a review of potential role of peripheral blood based biomarkers. / Jani, Bhautesh D.; McLean, Gary; Nicholl, Barbara I.; Barry, Sarah J.E.; Sattar, Naveed; Mair, Frances S.; Cavanagh, Jonathan.

In: Frontiers in Human Neuroscience, Vol. 9, 18, 02.02.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Risk assessment and predicting outcomes in patients with depressive symptoms

T2 - Frontiers in Human Neuroscience

AU - Jani, Bhautesh D.

AU - McLean, Gary

AU - Nicholl, Barbara I.

AU - Barry, Sarah J.E.

AU - Sattar, Naveed

AU - Mair, Frances S.

AU - Cavanagh, Jonathan

PY - 2015/2/2

Y1 - 2015/2/2

N2 - Depression is one of the major global health challenges and a leading contributor of health related disability and costs. Depression is a heterogeneous disorder and current methods for assessing its severity in clinical practice rely on symptom count, however this approach is unreliable and inconsistent. The clinical evaluation of depressive symptoms is particularly challenging in primary care, where the majority of patients with depression are managed, due to the presence of co-morbidities. Current methods for risk assessment of depression do not accurately predict treatment response or clinical outcomes. Several biological pathways have been implicated in the pathophysiology of depression; however, accurate and predictive biomarkers remain elusive. We conducted a systematic review of the published evidence supporting the use of peripheral biomarkers to predict outcomes in depression, using Medline and Embase. Peripheral biomarkers in depression were found to be statistically significant predictors of mental health outcomes such as treatment response, poor outcome and symptom remission; and physical health outcomes such as increased incidence of cardiovascular events and deaths, and all-cause mortality. However, the available evidence has multiple methodological limitations which must be overcome to make any real clinical progress. Despite extensive research on the relationship of depression with peripheral biomarkers, its translational application in practice remains uncertain. In future, peripheral biomarkers identified with novel techniques and combining multiple biomarkers may have a potential role in depression risk assessment but further research is needed in this area.

AB - Depression is one of the major global health challenges and a leading contributor of health related disability and costs. Depression is a heterogeneous disorder and current methods for assessing its severity in clinical practice rely on symptom count, however this approach is unreliable and inconsistent. The clinical evaluation of depressive symptoms is particularly challenging in primary care, where the majority of patients with depression are managed, due to the presence of co-morbidities. Current methods for risk assessment of depression do not accurately predict treatment response or clinical outcomes. Several biological pathways have been implicated in the pathophysiology of depression; however, accurate and predictive biomarkers remain elusive. We conducted a systematic review of the published evidence supporting the use of peripheral biomarkers to predict outcomes in depression, using Medline and Embase. Peripheral biomarkers in depression were found to be statistically significant predictors of mental health outcomes such as treatment response, poor outcome and symptom remission; and physical health outcomes such as increased incidence of cardiovascular events and deaths, and all-cause mortality. However, the available evidence has multiple methodological limitations which must be overcome to make any real clinical progress. Despite extensive research on the relationship of depression with peripheral biomarkers, its translational application in practice remains uncertain. In future, peripheral biomarkers identified with novel techniques and combining multiple biomarkers may have a potential role in depression risk assessment but further research is needed in this area.

KW - peripheral biomarkers

KW - depression

KW - treatment response

KW - risk assessment

KW - major depressive disorder

KW - MDD

U2 - 10.3389/fnhum.2015.00018

DO - 10.3389/fnhum.2015.00018

M3 - Article

VL - 9

JO - Frontiers in Human Neuroscience

JF - Frontiers in Human Neuroscience

SN - 1662-5161

M1 - 18

ER -